You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

102 Results
Document
Aug 2017
Document
Aug 2017
Document
Aug 2017
Guidelines and Advice
Status: Current
ID: GL-C50-09
Jun 2019
Document
Oct 2017
Symptom Management
Symptom Management
Drug
Other Name(s): Anandron® ()
Quick Link(s):
Drug Monograph, Patient Info Sheet
Sep 2018
Drug
Other Name(s): Tasigna®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Dec 2023
Drug
Other Name(s): Atriance®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Apr 2024
Regimen
Cancer Type:
Breast
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Nab-Paclitaxel - Metastatic Breast Cancer
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
nab-PACLitaxel
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Nov 2023
Regimen
Cancer Type:
Hematologic, 
Leukemia - Chronic Myeloid (CML)
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    niLOtinib - Chronic phase Ph+ CML, with specific criteria
Exceptional Access Program
    niLOtinib - Accelerated phase Ph+ CML with documented resistance or intolerance to imatinib therapy, with specific criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
niLOtinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Mar 2023

Pages